Gene editing aimed at the faulty gene behind a childhood brain tumor
Original title: CRISPR-Mediated Targeting of BRAF Oncogenes in Pediatric Low-Grade Glioma
How far along is this research?
This is a preprint. Other scientists have not checked it yet, so treat it as an early signal rather than an answer.
This was only done on cells in a dish, not in people.
The short version
This was lab work on cells in a dish, not a test in children.
What was studied. Researchers built CRISPR gene editing tools to switch off a faulty BRAF gene. That gene drives the most common brain tumor in children. The tools were tested on human cancer cells grown in the lab, including glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary cells taken from a patient.
What they found. The tools cut the target gene in a large share of cells. One tool worked in 66% of cells, and two others worked in 84% and 85%. A tool aimed at a single-letter gene change worked in about 57% of one cell type and about 74% of the patient glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary cells. A lab test showed the faulty gene piece had been cut out.
What this means, and what it doesn't
What it could mean: The idea of a one-time gene fix for this tumor is worth studying further. Today's drugs for it must be taken every day and can cause harm over time. This work is a first step toward a different approach, nothing more.
What it doesn't mean: This does not mean a new treatment exists or is coming soon. The work was done only in cells in a dish. No child has been treated with it. It has not been tested in animals or in people. It is not a promise of a cure, and it is far from everyday care. Many years of testing would be needed first.
Source: bioRxiv (preprint), August 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.